25% Higher UK Cost/QALY Threshold Isn’t Same As 25% Drug Price Hike

The United States and United Kingdom recently reached a prescription drug deal aimed at ensuring tariff-free U.K. exports of medicines, active pharmaceutical ingredients, and medical devices to the U.S. for at least three years. In return, the U.K. has agreed to increase its spending on newly approved pharmaceuticals. One of the key components of this agreement is a 25% increase in the numeric value of the metric that helps determine whether a health intervention is worth the cost.

Starting in April 2026, the National Institute for Health and Care Excellence (NICE) will raise its cost-effectiveness threshold from £20,000–£30,000 per quality-adjusted life year to £25,000–£35,000. This adjustment, which converts to $33,223–$45,512 at the current exchange rate, is expected to result in up to three to five new drugs or supplemental indications that were previously just above the old cost-effectiveness threshold being recommended by NICE in the future.

In addition to increasing the threshold, the U.K. government has introduced a new “value set for measuring quality of life,” which will likely involve greater input from the public. The government also plans to reduce the clawback rate to 15%, whereby drug companies pay a mandatory levy on sales of branded prescription medicines to the National Health Service, with the funds going back into the health service.

While the increase in the cost-effectiveness threshold may make it easier for higher-priced drugs to gain approval from NICE, it does not directly impact what British patients pay out-of-pocket. Pharmaceutical companies will still need to demonstrate the clinical effectiveness of their drugs compared to existing standards of care in order to justify potential price increases.

It is important to note that the cost-effectiveness threshold is just one of several factors considered when determining the pricing of medicines. NICE evaluates approximately 70 prescription drugs annually and grants a positive recommendation to 91% of them. The agency uses a higher threshold for medicines that treat ultra-rare conditions and has been gradually increasing the threshold, particularly in therapeutic categories like cancer.

The recent changes in the cost-effectiveness threshold have been viewed as a signal to the life sciences sector, influencing investment decisions, pharmaceutical pricing, and even the types of clinical trials conducted in the U.K. The Association of the British Pharmaceutical Industry has advocated for a larger increase in the threshold than what the government has implemented, suggesting a threshold of £40,000–£50,000 ($53,272–$66,590) indexed to inflation.

The government’s Spending Review document anticipates the need for an additional budget of £3.3 ($4.4) billion over the next three years to accommodate the increase in the threshold. Without external funding, this could create a budget shortfall in the NHS, potentially leading to cuts in other areas of the healthcare system. Ultimately, the impact of these changes on patients, pharmaceutical companies, and the healthcare system as a whole remains to be seen. The ongoing discussion around increasing the threshold without a guaranteed budgetary expansion has raised concerns about the potential impact on patients’ health. While the possibility of more expensive new drugs gaining market access is enticing, there is a risk that other patients could be harmed in the process.

The recent deal between the U.K. and U.S. governments on tariffs and spending on pharmaceuticals has left many unanswered questions about its implications for drug prices. It is crucial to carefully consider the consequences of any changes to the threshold and ensure that patient safety remains a top priority.

One of the key points of contention is the lack of a guaranteed budgetary expansion to accompany the proposed threshold increase. Without adequate funding to support the higher threshold, there is a risk that patients could face limited access to essential medications or be forced to pay exorbitant prices out of pocket.

Furthermore, the potential for more expensive drugs to enter the market without sufficient oversight could have serious implications for patient outcomes. It is essential to strike a balance between promoting innovation and ensuring that patients have access to affordable and effective treatments.

As the debate continues, it is important for policymakers to carefully consider the long-term implications of any changes to the threshold. By prioritizing patient safety and ensuring adequate funding for healthcare services, we can work towards a healthcare system that benefits all patients.